| Iheanyi Nnamdi Amanwanne, NP PSYCH | |
|
2500 E Van Buren St, Phoenix, AZ 85008-6037 | |
| (602) 685-3100 | |
| Not Available |
| Full Name | Iheanyi Nnamdi Amanwanne |
|---|---|
| Gender | Male |
| Speciality | Clinical Nurse Specialist - Psychiatric/mental Health |
| Location | 2500 E Van Buren St, Phoenix, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639883028 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0808X | Clinical Nurse Specialist - Psychiatric/mental Health | 282935 (Arizona) | Primary |
| Entity Name | Divine Wellness Psychiatric Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245007210 PECOS PAC ID: 8123461464 Enrollment ID: O20240203000152 |
News Archive
Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.
Compounds tested for their potential as antibiotics have demonstrated promising activity against one of the deadliest infectious diseases - tuberculosis (TB).
Schering-Plough Corp. has announced that the European Medicines Agency (EMEA) has validated (accepted for review) its Marketing Authorization Application (MAA) for corifollitropin alfa, the company's experimental, sustained follicle stimulant (SFS).
Gov. Bob McDonnell added the provision Monday to recently passed legislation. Meanwhile, in other news, the Maryland Senate could vote as early as today on a bill that implements the state's new insurance marketplace and Louisiana insurers and nonprofits form group to help consumers understand new insurance options.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Iheanyi Nnamdi Amanwanne, NP PSYCH 3880 W Ranier Ct, Anthem, AZ 85086-8018 Ph: (602) 465-6011 | Iheanyi Nnamdi Amanwanne, NP PSYCH 2500 E Van Buren St, Phoenix, AZ 85008-6037 Ph: (602) 685-3100 |
News Archive
Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.
Compounds tested for their potential as antibiotics have demonstrated promising activity against one of the deadliest infectious diseases - tuberculosis (TB).
Schering-Plough Corp. has announced that the European Medicines Agency (EMEA) has validated (accepted for review) its Marketing Authorization Application (MAA) for corifollitropin alfa, the company's experimental, sustained follicle stimulant (SFS).
Gov. Bob McDonnell added the provision Monday to recently passed legislation. Meanwhile, in other news, the Maryland Senate could vote as early as today on a bill that implements the state's new insurance marketplace and Louisiana insurers and nonprofits form group to help consumers understand new insurance options.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).
› Verified 9 days ago
Kassandra Hyde, APRN Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 5777 E Mayo Blvd, Phoenix, AZ 85054 Phone: 480-342-3962 | |
Lara Shleef, PA Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 750 E Thunderbird Rd Ste 1-3, Phoenix, AZ 85022 Phone: 602-682-7455 Fax: 602-218-6383 | |
Cathleen Murphy-taylor, Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1919 E Thomas Rd, Phoenix, AZ 85016 Phone: 602-509-6914 | |
Katie Marie Williams, CRNP Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 4545 E Shea Blvd, 175, Phoenix, AZ 85028 Phone: 866-662-4560 Fax: 877-561-7566 | |
Mrs. Frances Marie Hanumaiah, ACNS-BC Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 650 E Indian School Rd, Phoenix, AZ 85012 Phone: 602-277-5551 | |
Emily Jacobs, APRN Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1747 E Northern Ave Unit 256, Phoenix, AZ 85020 Phone: 734-604-6014 | |
Ms. Patricia Kate Paradis, FNP-C Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 10046 N Metro Pkwy W, Suite 115, Phoenix, AZ 85051 Phone: 602-674-5515 |